08.02.10
Charles River Laboratories 2Q10
2Q Revenues: $292 million (-5%)
2Q Earnings: $15 million (-57%)
YTD Revenues: $589 million (-3%)
YTD Earnings: $31 million (-46%)
Comments: The Research Models and Services (RMS) unit was flat at $166 million for the quarter. Gains from In vitro products were offset by lower sales of large models. The Preclinical Services (PCS) business saw revenues drop 12% to $125 million in 2Q10, driven by lower prices and reduced demand. The PCS unit reported more short-term, less complex studies. For 1H10, RMS revenues were up 4% to $339 million, while PCS sales were down 12% to $250 million.
2Q Revenues: $292 million (-5%)
2Q Earnings: $15 million (-57%)
YTD Revenues: $589 million (-3%)
YTD Earnings: $31 million (-46%)
Comments: The Research Models and Services (RMS) unit was flat at $166 million for the quarter. Gains from In vitro products were offset by lower sales of large models. The Preclinical Services (PCS) business saw revenues drop 12% to $125 million in 2Q10, driven by lower prices and reduced demand. The PCS unit reported more short-term, less complex studies. For 1H10, RMS revenues were up 4% to $339 million, while PCS sales were down 12% to $250 million.
